-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Forma Therapeutics (NASDAQ:FMTX) Sees Unusually-High Trading Volume
Forma Therapeutics (NASDAQ:FMTX) Sees Unusually-High Trading Volume
Shares of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX – Get Rating) saw strong trading volume on Friday . 36,469 shares changed hands during trading, a decline of 95% from the previous session's volume of 788,493 shares.The stock last traded at $20.00 and had previously closed at $20.24.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on the stock. HC Wainwright lowered shares of Forma Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the company from $53.00 to $20.00 in a research report on Friday. SVB Leerink cut their price objective on shares of Forma Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a research report on Friday, May 27th. Cantor Fitzgerald lowered shares of Forma Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Thursday. Credit Suisse Group lowered shares of Forma Therapeutics from an "outperform" rating to a "neutral" rating and set a $20.00 price objective on the stock. in a research report on Friday. Finally, Jefferies Financial Group downgraded Forma Therapeutics from a "buy" rating to a "hold" rating and lowered their price target for the company from $28.00 to $20.00 in a report on Friday. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $29.17.
Get Forma Therapeutics alerts:Forma Therapeutics Price Performance
The firm has a fifty day simple moving average of $9.50 and a 200 day simple moving average of $8.52. The company has a market cap of $956.10 million, a price-to-earnings ratio of -5.00 and a beta of 0.24.
Institutional Investors Weigh In On Forma Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of FMTX. Quantbot Technologies LP grew its stake in shares of Forma Therapeutics by 125.0% in the first quarter. Quantbot Technologies LP now owns 3,600 shares of the company's stock worth $33,000 after acquiring an additional 2,000 shares during the last quarter. Advisor Group Holdings Inc. grew its stake in shares of Forma Therapeutics by 17,885.7% in the first quarter. Advisor Group Holdings Inc. now owns 2,518 shares of the company's stock worth $33,000 after acquiring an additional 2,504 shares during the last quarter. Amalgamated Bank acquired a new stake in shares of Forma Therapeutics in the first quarter worth $38,000. US Bancorp DE grew its stake in shares of Forma Therapeutics by 282.5% in the first quarter. US Bancorp DE now owns 4,341 shares of the company's stock worth $40,000 after acquiring an additional 3,206 shares during the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Forma Therapeutics by 56.3% in the second quarter. Legal & General Group Plc now owns 10,187 shares of the company's stock worth $70,000 after acquiring an additional 3,670 shares during the last quarter. Institutional investors and hedge funds own 87.39% of the company's stock.About Forma Therapeutics
(Get Rating)
Forma Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer.
Featured Stories
- Get a free copy of the StockNews.com research report on Forma Therapeutics (FMTX)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Forma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX – Get Rating) saw strong trading volume on Friday . 36,469 shares changed hands during trading, a decline of 95% from the previous session's volume of 788,493 shares.The stock last traded at $20.00 and had previously closed at $20.24.
週五，Forma治療控股公司(納斯達克代碼：FMTX-GET評級)的股票成交量強勁。36,469股股票在交易中易手，較前一交易日的788,493股下跌了95%。該股最新報20.00美元，此前收盤報20.24美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Several equities analysts recently weighed in on the stock. HC Wainwright lowered shares of Forma Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the company from $53.00 to $20.00 in a research report on Friday. SVB Leerink cut their price objective on shares of Forma Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a research report on Friday, May 27th. Cantor Fitzgerald lowered shares of Forma Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Thursday. Credit Suisse Group lowered shares of Forma Therapeutics from an "outperform" rating to a "neutral" rating and set a $20.00 price objective on the stock. in a research report on Friday. Finally, Jefferies Financial Group downgraded Forma Therapeutics from a "buy" rating to a "hold" rating and lowered their price target for the company from $28.00 to $20.00 in a report on Friday. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $29.17.
幾位股票分析師最近對該股進行了加碼。在週五的一份研究報告中，HC Wainwright將Forma治療公司的股票評級從“買入”下調至“中性”，並將該公司的目標價從53.00美元下調至20.00美元。SVB Leerink在5月27日星期五的一份研究報告中將Forma Treateutics的股票目標價從25.00美元下調至23.00美元，並對該股設定了“跑贏大盤”的評級。在週四的一份研究報告中，坎託·菲茨傑拉德將Forma治療公司的股票評級從“增持”下調至“中性”。瑞士信貸集團將Forma Treateutics的股票評級從“跑贏大盤”下調至“中性”，併為該股設定了20.00美元的目標價。在週五的一份研究報告中。最後，傑富瑞金融集團在週五的一份報告中將Forma治療公司的評級從“買入”下調至“持有”，並將該公司的目標價從28.00美元下調至20.00美元。五位分析師對該股的評級為持有，一位分析師對該股的評級為買入。根據MarketBeat的數據，該股目前的平均評級為持有，平均目標價為29.17美元。
Forma Therapeutics Price Performance
Forma治療公司的價格表現
The firm has a fifty day simple moving average of $9.50 and a 200 day simple moving average of $8.52. The company has a market cap of $956.10 million, a price-to-earnings ratio of -5.00 and a beta of 0.24.
該公司的50日簡單移動均線為9.50美元，200日簡單移動均線為8.52美元。該公司市值為9.561億美元，市盈率為-5.00倍，貝塔係數為0.24。
Institutional Investors Weigh In On Forma Therapeutics
機構投資者對Forma Treeutics的看法
About Forma Therapeutics
關於Forma Treateutics
(Get Rating)
(獲取評級)
Forma Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer.
Forma治療控股公司是一家臨牀階段的生物製藥公司，專注於治療罕見血液疾病和癌症的新療法的開發和商業化。其待開發的核心產品包括FT-4202，這是治療鐮狀細胞疾病和其他血紅蛋白疾病的第一階段試驗；以及FT-7051，用於治療轉移性去勢抵抗前列腺癌。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Forma Therapeutics (FMTX)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- 免費獲取StockNews.com關於Forma治療(FMTX)的研究報告
- 隨着管理層重組，股市能否迅速反彈？
- MarketBeat：回顧中的一週8/29-9/2
- 霍梅爾在這些水平上看起來很便宜
- 露露檸檬將飆升至9月
- 耐克股票會被超賣，但仍被高估嗎？
Receive News & Ratings for Forma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Forma治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Forma Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧